New hope for patients with rare, Treatment-Resistant immune disorder
NCT ID NCT07085039
Summary
This study is testing the drug ruxolitinib for adults with a rare immune system disorder called idiopathic Multicentric Castleman Disease (iMCD) that hasn't improved with standard treatments. The goal is to see if ruxolitinib can help control symptoms like severe fatigue, fever, and night sweats, and reduce swollen lymph nodes. Researchers will measure improvements in symptoms and lab tests over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.